Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $75.00 Consensus Target Price from Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received a consensus recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $75.00.

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th.

Reviva Pharmaceuticals Price Performance

NASDAQ:RVPH opened at $0.53 on Thursday. The business has a fifty day simple moving average of $0.51 and a two-hundred day simple moving average of $1.08. Reviva Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $17.20. The company has a market capitalization of $6.98 million, a P/E ratio of -0.29 and a beta of 0.50.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.19. As a group, analysts anticipate that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of RVPH. XTX Topco Ltd bought a new position in shares of Reviva Pharmaceuticals in the second quarter valued at approximately $31,000. Lido Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 3rd quarter valued at about $37,000. NewEdge Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 1st quarter valued at about $58,000. State Street Corp grew its holdings in shares of Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.